Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study probes emotional impact of Cutting-Edge prostate cancer scans

NCT ID NCT06523777

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how a new, more sensitive type of PET scan (PSMA PET) affects the anxiety, decision-making, and quality of life of 350 men with prostate cancer. Participants will fill out surveys about their feelings and experiences over a year. The goal is to understand the real-world impact of this advanced imaging technology.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with documented diagnosis of prostate cancer undergoing PSMA-PET imaging, including participants along the disease spectrum (all grades, stages, and indications for imaging). Participants will be identified and screened from all referrals to PET imaging and contacted by a study coordinator.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented diagnosis of prostate cancer * Scheduled for their FIRST PSMA PET scan for prostate cancer * English-speaking * Willing and able to complete 4 surveys electronically or on paper at 3 timepoints (within 1 month after PET scan, 3-6 months, 12 months) * Able to use mobile device (smartphone or tablet) or computer with web access to complete study surveys or able to complete paper surveys Exclusion Criteria: * Lack of access to a mobile device (smartphone or tablet) or computer with web access or unable to receive surveys by mail. * Unable to give consent and be enrolled * PET scan is being conducted within a clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Griffin Hospital

    Derby, Connecticut, 06418, United States

  • Radiology and Biomedical Imaging - New Haven - Smilow Cancer Hospital (North Pavilion):

    New Haven, Connecticut, 06520, United States

  • Saint Raphael's Radiology and Biomedical Imaging, Basement Location.

    New Haven, Connecticut, 06520, United States

  • Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center

    Bridgeport, Connecticut, 06611, United States

  • Yale New Haven Health Greenwich Hospital

    Greenwich, Connecticut, 06830, United States

  • Yale New Haven Health Lawrence & Memorial Hospital

    New London, Connecticut, 06320, United States

  • Yale New Haven Health Westerly Hospital

    Westerly, Rhode Island, 02891, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.